Experienced medical technology leader to guide Amber Implants’ transition from development to commercialization following FDA approval of VCFix® Spinal System Company preparing for US market launch in 2026
THE HAGUE, Netherlands, Nov. 6, 2025 /PRNewswire/ — Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announced the appointment of Vincent Gardès as CEO, effective immediately, following his four-year term as Chairman of the Board of Directors. This strategic leadership transition marks an important milestone as Amber Implants moves from its development phase to commercialization, following the recent FDA approval of the VCFix® spinal system.
Dr. Banafsheh Sajadi, co-founder and current CEO, will continue to serve as COO and CEO, working closely with Vincent to drive the company’s growth and expansion.
With 30 years of international leadership experience in the MedTech sector in Europe and the US, Vincent brings deep experience in business strategy, market expansion and value creation. He has successfully guided several companies through critical phases of growth and commercialization, including his tenure as CEO of Vexim, where he transformed the spinal implant company from an early-stage company to a profitable international organization, ultimately leading to a successful initial public offering and acquisition by Stryker in 2017. Vincent has since held senior leadership and advisory roles at Truffle Capital, Kumovis and Germitec, where he has played a key role in the global expansion and commercial launch of the company in the past. five years.
Vincent Gardès, CEO of Amber Implants, commented: “Amber’s VCFix® technology represents a significant innovation in spinal fracture care and I see tremendous potential as we prepare for US market entry and global commercialization. I look forward to working with the talented team to bring this innovative solution to surgeons and patients around the world.”
Dr. Banafsheh Sajadi, co-founder, COO and CEO of Amber Implants, added: “Vincent brings extensive business experience and a proven track record in scaling medical technology companies, which aligns perfectly with the founders’ vision and next phase of growth for Amber Implants. Together, we are fully committed to advancing the treatment of spinal fractures through innovation and expanding our global impact.”
Under new leadership, Amber Implants will focus on accelerating U.S. market entry and commercialization of the VCFix® spinal system, creating strategic partnerships and expanding operations to meet growing global demand. The company is now firmly positioned as a commercial-stage company, preparing for US launch in 2026. Backed by strong global patent protection and continued development of its Spinoza fixation systems portfolio, Amber Implants is on track to capture a significant share of the more than €2 billion global vertebral compression fracture market by 2029.
The recent FDA approval of the VCFix® spinal system not only accelerates adoption and revenue growth, but also serves as a gateway to additional global markets where FDA approval is recognized.
About amber implants
Amber Implants is a commercial-stage medical technology company with operations in the Netherlands and the U.S. Founded in 2018, the company develops next-generation implants for spinal injuries, with the goal of improving patient outcomes through more natural healing and greater spinal stability. Its flagship product, the VCFix® Spinal System, offers a simpler, more efficient and safer approach to treating a wide range of spinal fractures.
Amber Implants is backed by its founders, venture capital investors, angel investors and non-dilutive government funding. In 2025, the company obtained FDA 510(k) clearance for the VCFix® spinal system, marking an important step toward US commercialization in 2026 and establishing a solid foundation for its next phase of growth.
SOURCE Amber Implants
